Ligand validation:4YDI

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 4YDI designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4YDI_NAG_G_503	48%	79%	0.179	0.921	0.26	0.6	-	1	0	0	100%	0.9333
4YDI_NAG_G_507	30%	78%	0.252	0.915	0.34	0.54	-	-	0	0	100%	0.9333
4YDI_NAG_G_504	20%	80%	0.246	0.851	0.38	0.46	-	-	1	0	100%	0.9333
4YDI_NAG_L_301	17%	87%	0.213	0.791	0.25	0.45	-	-	0	0	100%	0.9333
4YDI_NAG_G_508	17%	89%	0.271	0.85	0.21	0.43	-	-	0	0	100%	0.9333
4YDI_NAG_G_506	15%	87%	0.27	0.829	0.33	0.36	-	-	0	0	100%	0.9333
4YDI_NAG_G_501	12%	89%	0.288	0.821	0.26	0.38	-	-	0	0	100%	0.9333
4YDI_NAG_G_502	4%	83%	0.341	0.704	0.25	0.53	-	-	0	0	100%	0.9333
4YDI_NAG_G_505	3%	85%	0.337	0.682	0.18	0.56	-	-	0	0	100%	0.9333
4YDI_NAG_G_510	2%	88%	0.281	0.566	0.28	0.38	-	-	0	0	100%	0.9333
4YDI_NAG_G_511	1%	81%	0.523	0.741	0.35	0.47	-	-	0	0	100%	0.9333
4YDI_NAG_G_512	1%	86%	0.472	0.681	0.26	0.46	-	-	0	0	100%	0.9333
4YDI_NAG_G_509	0%	74%	0.796	0.583	0.43	0.57	-	-	2	0	100%	0.9333
4J6R_NAG_G_504	71%	68%	0.118	0.939	0.49	0.74	-	-	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.